Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
Verrica Pharmaceuticals (Nasdaq: VRCA) will report first-quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026 at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) will report first-quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026 at 4:30 p.m. ET.
The company will host a conference call and live webcast; domestic and international dial-in numbers and a conference ID (VERRICA) are provided. A webcast replay will be archived on Verrica's investor website for 90 days.
Details
News Market Reaction – VRCA
On May 5, the day this news came out, VRCA closed 12.58% above the previous close.
Data tracked by StockTitan Argus for the May 5 session.
Key Figures
- Current price
- $6.36
- Pre-news close for VRCA
- Price vs 52-week high
- -35.24%
- Relative to 52-week high of $9.8212
- Price vs 52-week low
- 93.9%
- Relative to 52-week low of $3.28
- Conference time
- 4:30 p.m. ET
- Q1 2026 results call on May 12, 2026
- Webcast replay
- 90 days
- Replay of May 12, 2026 conference call
- Shares registered
- 14,756,230 shares
- Common stock registered for resale under S-3 shelf
- Shares outstanding
- 17,178,786 shares
- Common stock outstanding as of Apr 8, 2026 (DEF 14A)
- New equity pool
- 1,756,257 shares
- Additional shares in Amended 2018 Equity Incentive Plan
Previous Earnings date Reports
-
Announcement of Q4 and full-year 2025 results call and webcast timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026, to discuss the Company's financial results for the first quarter ending March 31, 2026, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-833-316-2483 (domestic) or 1-785-838-9284 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.